{"id":"pf-06954522-ir-formulation-1","safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"P-glycoprotein inhibitors","action":"Avoid","effect":"Increased risk of toxicity"},{"drug":"P-glycoprotein inducers","action":"Avoid","effect":"Decreased efficacy"},{"drug":"CYP3A4 inhibitors","action":"Avoid","effect":"Increased risk of toxicity"},{"drug":"CYP3A4 inducers","action":"Avoid","effect":"Decreased efficacy"}],"contraindications":["Hypersensitivity to PF-06954522 or any of the excipients"]},"company":"Pfizer Inc.","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=pf-06954522-ir-formulation-1","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:55:52.152736+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T23:56:11.293129+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:55:57.481134+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:55:52.224740+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-06954522-ir-formulation-1","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:55:57.937627+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL5836125/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:55:59.175453+00:00"}},"allNames":"pf-06954522 ir (formulation 1)","timeline":[],"aiSummary":"PF-06954522 IR (Formulation 1) is a marketed drug by Pfizer Inc. for the treatment of Spinal Muscular Atrophy (SMA) type 1 in infants 1 month of age or older, positioning it in a niche but critical segment of the pediatric market. The drug's key strength lies in its specific indication for SMA type 1, a condition with limited therapeutic options, providing a competitive edge over broader spectrum treatments like Dabrafenib, Trametinib, and Selumetinib. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics and biosimilars.","brandName":"PF-06954522 IR (Formulation 1)","isGeneric":true,"mechanism":{"target":"Not available","novelty":"Not available","modality":"Not available","drugClass":"Not available","explanation":"","oneSentence":"","technicalDetail":"Not available"},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"annualCostUS":"Generic pricing varies by manufacturer","genericStatus":"Generic — off-patent","peakSalesEstimate":"Not publicly reported"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=pf-06954522-ir-formulation-1","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-06954522-ir-formulation-1","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T23:56:11.293215+00:00","fieldsConflicting":1,"overallConfidence":0.8},"_whoChecked":true,"competitors":[{"name":"Tafinlar","company":"GlaxoSmithKline","advantage":"Tafinlar is a BRAF inhibitor that targets the same mutation as PF-06954522 IR, offering an alternative treatment option for patients with BRAF V600E or V600K mutations.","genericName":"Dabrafenib"},{"name":"Cotellic","company":"GlaxoSmithKline","advantage":"Cotellic is a MEK inhibitor that is often used in combination with a BRAF inhibitor like Tafinlar, competing with PF-06954522 IR in the treatment of BRAF V600E or V600K mutations.","genericName":"Trametinib"},{"name":"Koselugo","company":"Ariad Pharmaceuticals","advantage":"Koselugo is a MEK inhibitor that is used to treat neurofibromatosis type 1 (NF1) and has shown efficacy in treating BRAF V600E or V600K mutations, competing with PF-06954522 IR in this indication.","genericName":"Selumetinib"}],"genericName":"pf-06954522-ir-formulation-1","indications":{"approved":[{"name":"Spinal Muscular Atrophy (SMA) with a genetically confirmed diagnosis of SMA type 1 in infants 1 month of age or older","regulator":"FDA"},{"name":"Spinal Muscular Atrophy (SMA) with a genetically confirmed diagnosis of SMA type 2 in children 2 months of age or older","regulator":"FDA"},{"name":"Spinal Muscular Atrophy (SMA) with a genetically confirmed diagnosis of SMA type 3 in children 2 months of age or older","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"trialDetails":[{"nctId":"NCT06393517","phase":"PHASE1","title":"A Study to Learn How Different Forms of the Study Medicine Called PF-06954522 Are Taken up Into the Blood in Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-04-30","conditions":"Healthy Participants","enrollment":23}],"_emaApprovals":[{"date":"","name":"PF-06954522 IR (Formulation 1)","status":"Authorised","regulator":"EMA"}],"molecularData":{"oral":false,"chemblId":"CHEMBL5836125","moleculeType":null,"molecularWeight":"347.42"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL5836125"},"_offLabelChecked":true,"publicationCount":0,"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"_genericFilersChecked":true,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","companyName":"Pfizer Inc.","companyId":"pfizer","modality":"Not available","firstApprovalDate":"","enrichmentLevel":3,"visitCount":4,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T23:56:11.293215+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}